-

Alto Neuroscience to Participate in the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit

LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience today announced that founder and chief executive officer, Amit Etkin, M.D., Ph.D., will participate in a technologies panel at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit on Monday, September 19, 2022 at 4:15 p.m. ET, which is being hosted virtually. The webcast of the panel discussion will be accessible to those registered to attend the summit.

About Alto Neuroscience

Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines to help patients get better faster. Differences in individuals’ biology impact how they respond to treatment. Alto’s human data-driven platform measures brain biomarkers including EEG activity and behavioral patterns, wearable data, genetics, and other factors, to match each patient with the right Alto therapy. The company’s clinical-stage pipeline includes drug candidates being studied in mental health conditions targeting cognition, emotion, and sleep processes. For more information, visit https://www.altoneuroscience.com or follow us on Twitter.

Contacts

Investor Contact
Nick Smith
corporate@altoneuroscience.com

Media Contact
Jordann Phillips
media@altoneuroscience.com

Industry:

Alto Neuroscience

Release Versions
English

Contacts

Investor Contact
Nick Smith
corporate@altoneuroscience.com

Media Contact
Jordann Phillips
media@altoneuroscience.com

Social Media Profiles
Alto Neuroscience
Alto Neuroscience
More News From Alto Neuroscience

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “The second quarter further strengthened the case for ALTO-207 and our conviction in the opportunity ahead of it,” said A...

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of $26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected...

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study was conducted and independently funded by investigators at Lund University, Sweden. Adults with elevated baseline anhedonia symptoms with a diagnosis of major d...
Back to Newsroom